Despite the cloning of the CFTR gene in 1989, significant progress in the development of CFTR-targeting therapies has only occurred in the past decade, when CFTR modulators, the first molecular treatments directly targeting the underlying molecular defect of CF, were approved. The gene discussed is CFTR; the disease is cystic fibrosis.